
Sign up to save your podcasts
Or


Moderna pops on “robust” early results on its Covid-19 vaccine candidate, but will it pass the next big test? UnitedHealth’s 2nd-quarter profits are much higher than expected, but executives are quick to point out why investors shouldn’t get too excited. Emily Flippen analyzes those stories and shares why she’ll be watching Chinese search giant Baidu this earnings season.
By The Motley Fool4.7
16041,604 ratings
Moderna pops on “robust” early results on its Covid-19 vaccine candidate, but will it pass the next big test? UnitedHealth’s 2nd-quarter profits are much higher than expected, but executives are quick to point out why investors shouldn’t get too excited. Emily Flippen analyzes those stories and shares why she’ll be watching Chinese search giant Baidu this earnings season.

3,214 Listeners

1,714 Listeners

806 Listeners

945 Listeners

517 Listeners

4,352 Listeners

1,634 Listeners

825 Listeners

5,136 Listeners

673 Listeners

9,514 Listeners

1,032 Listeners

344 Listeners

301 Listeners

1,294 Listeners

1,553 Listeners

78 Listeners